Journal of Hepatology
Volume 54, Issue 1 , Pages 115-121 , January 2011

AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice

  • Jeannette Cany

      Affiliations

    • INSERM U948, Biothérapies Hépatiques, Nantes, France
    • Université de Nantes, Nantes Atlantique Universités, EA4274, Nantes, France
    • Institut des Maladies de l’Appareil Digestif – IMAD, CHU Hôtel Dieu, Nantes, France
    • ,
  • Benoît Barteau

      Affiliations

    • INSERM U915, Institut du Thorax, Faculté de Médecine, Nantes, France
    • In-Cell-Art, 1 place Alexis Ricordeau, Nantes, France
    • ,
  • Lucile Tran

      Affiliations

    • INSERM U948, Biothérapies Hépatiques, Nantes, France
    • Université de Nantes, Nantes Atlantique Universités, EA4274, Nantes, France
    • Institut des Maladies de l’Appareil Digestif – IMAD, CHU Hôtel Dieu, Nantes, France
    • ,
  • Vanessa Gauttier

      Affiliations

    • INSERM U948, Biothérapies Hépatiques, Nantes, France
    • Université de Nantes, Nantes Atlantique Universités, EA4274, Nantes, France
    • Institut des Maladies de l’Appareil Digestif – IMAD, CHU Hôtel Dieu, Nantes, France
    • ,
  • Isabelle Archambeaud

      Affiliations

    • INSERM U948, Biothérapies Hépatiques, Nantes, France
    • Université de Nantes, Nantes Atlantique Universités, EA4274, Nantes, France
    • Institut des Maladies de l’Appareil Digestif – IMAD, CHU Hôtel Dieu, Nantes, France
    • ,
  • Jean-Pierre Couty

      Affiliations

    • INSERM U567, Institut Cochin, Paris, France
    • Université Paris Diderot, Paris, France
    • ,
  • Bruno Turlin

      Affiliations

    • Département d’Anatomie et Cytologie Pathologiques, CHU Pontchaillou, Rennes, France
    • ,
  • Bruno Pitard

      Affiliations

    • INSERM U915, Institut du Thorax, Faculté de Médecine, Nantes, France
    • In-Cell-Art, 1 place Alexis Ricordeau, Nantes, France
    • ,
  • Georges Vassaux

      Affiliations

    • INSERM U948, Biothérapies Hépatiques, Nantes, France
    • Université de Nantes, Nantes Atlantique Universités, EA4274, Nantes, France
    • Institut des Maladies de l’Appareil Digestif – IMAD, CHU Hôtel Dieu, Nantes, France
    • ,
  • Nicolas Ferry

      Affiliations

    • INSERM U948, Biothérapies Hépatiques, Nantes, France
    • Université de Nantes, Nantes Atlantique Universités, EA4274, Nantes, France
    • Institut des Maladies de l’Appareil Digestif – IMAD, CHU Hôtel Dieu, Nantes, France
    • ,
  • Sophie Conchon

      Affiliations

    • INSERM U948, Biothérapies Hépatiques, Nantes, France
    • Université de Nantes, Nantes Atlantique Universités, EA4274, Nantes, France
    • Institut des Maladies de l’Appareil Digestif – IMAD, CHU Hôtel Dieu, Nantes, France
    • Corresponding Author InformationCorresponding author. Address: INSERM U948, Biothérapies Hépatiques, CHU Hotel Dieu, 1 place A. Ricordeau, 44000 Nantes, France. Tel.: +33 (0) 240087507; fax: +33 (0) 240083048.

Received 5 March 2010 ,Revised 10 May 2010 ,Accepted 9 June 2010.

References 

  1. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–1763
  2. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48:S20–37
  3. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657–662
  4. Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004;10:1574–1579
  5. Goldfarb S, Pugh TD, Koen H, He YZ. Preneoplastic and neoplastic progression during hepatocarcinogenesis in mice injected with diethylnitrosamine in infancy. Environ Health Perspect. 1983;50:149–161
  6. Bowen DG, McCaughan GW, Bertolino P. Intrahepatic immunity: a tale of two sites?. Trends Immunol. 2005;26:512–517
  7. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet. 2009;373:673–683
  8. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006;12:2817–2825
  9. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, et al. T-cell responses to HLA-A∗0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003;9:5902–5908
  10. Osada T, Woo CY, McKinney M, Yang XY, Lei G, Labreche HG, et al. Induction of Wilms’ tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Clin Cancer Res. 2009;15:2789–2796
  11. Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Levy F, et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest. 2003;111:1673–1681
  12. Mulryan K, Ryan MG, Myers KA, Shaw D, Wang W, Kingsman SM, et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther. 2002;1:1129–1137
  13. Dai MS, Nitcheu-Tefit J, Alcock S, Ramirez-Jimenez F, Chao TY, Baril P, et al. Development of an Escherichia coli expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumors. J Immunother. 2009;32:845–855
  14. Nitcheu-Tefit J, Dai MS, Critchley-Thorne RJ, Ramirez-Jimenez F, Xu M, Conchon S, et al. Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25 high regulatory T cell function in vivo. J Immunol. 2007;179:1532–1541
  15. McIlroy D, Barteau B, Cany J, Richard P, Gourden C, Conchon S, et al. DNA/amphiphilic block copolymer nanospheres promote low-dose DNA vaccination. Mol Ther. 2009;17:1473–1481
  16. Pitard B, Bello-Roufai M, Lambert O, Richard P, Desigaux L, Fernandes S, et al. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Res. 2004;32:e159
  17. Cany J, Avril A, Pichard V, Aubert D, Ferry N, Conchon S. A transgenic mouse with beta-galactosidase as a fetal liver self-antigen for immunotherapy studies. J Hepatol. 2007;47:396–403
  18. Couty JP, Crain AM, Gerbaud S, Labasque M, Marchiol C, Fradelizi D, et al. Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine. Cancer Immunol Immunother. 2008;57:1161–1171
  19. Mitchell C, Couton D, Couty JP, Anson M, Crain AM, Bizet V, et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol. 2009;174:1766–1775
  20. Pichard V, Aubert D, Ferry N. Efficient retroviral gene transfer to the liver in vivo using nonpolypeptidic mitogens. Biochem Biophys Res Commun. 2001;286:929–935
  21. Zerbini A, Pilli M, Ferrari C, Missale G. Is there a role for immunotherapy in hepatocellular carcinoma?. Dig Liver Dis. 2006;38:221–225
  22. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer. 2005;41:1911–1922
  23. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol. 2008;48:858–879
  24. Koen H, Pugh TD, Nychka D, Goldfarb S. Presence of alpha-fetoprotein-positive cells in hepatocellular foci and microcarcinomas induced by single injections of diethylnitrosamine in infant mice. Cancer Res. 1983;43:702–708
  25. Pichard V, Royer PJ, Richou C, Cauchin E, Goebes K, Gaignerie A, et al. Detection, isolation, and characterization of alpha-fetoprotein-specific T cell populations and clones using MHC class I multimer magnetic sorting. J Immunother. 2008;31:246–253
  26. Grimm CF, Ortmann D, Mohr L, Michalak S, Krohne TU, Meckel S, et al. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology. 2000;119:1104–1112
  27. Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, et al. Alpha-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res. 2001;61:8782–8786
  28. Chang CC, Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother. 2007;56:227–236
  29. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002;3:999–1005
  30. Koopman LA, van Der Slik AR, Giphart MJ, Fleuren GJ. Human leukocyte antigen class I gene mutations in cervical cancer. J Natl Cancer Inst. 1999;91:1669–1677
  31. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88:100–108
  32. Maleno I, Cabrera CM, Cabrera T, Paco L, Lopez-Nevot MA, Collado A, et al. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics. 2004;56:244–253
  33. Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother. 2004;27:184–190

PII: S0168-8278(10)00717-8

doi: 10.1016/j.jhep.2010.06.027

Journal of Hepatology
Volume 54, Issue 1 , Pages 115-121 , January 2011

Article Tools

* Image Usage & Resolution